Lotos Pharma introduces a new and innovative product Spasmoil.
Almost everyone has experienced indigestion in their lifetime. Most commonly it is due to our eating habits, homogeneous food, increased stress, long-term use of medicinal products and harmful habits.
A survey conducted by Lotos Pharma in May 2019 shows that 98% of the respondents have experienced indigestion – heartburn, abdominal pain, bloating and constipation. The most common symptom was flatulence, which was reported by 36% of respondents and abdominal pain by 28%1. Pharmacists also acknowledge that the demand for medicinal products reducing the symptoms of indigestion is high in pharmacies.
Kaspars Ivanovs, Head of Lotos Pharma, about product development: “The problem of indigestion is topical not only in Latvia, but also all over the world, the range of medicinal products offered at the international pharmaceutical exhibitions, in which the company participates each year, verifies that. The idea of the new product to reduce the symptoms of indigestion came from the latest trends and studies that have shown the effectiveness of peppermint essential oil in reducing the symptoms of irritable bowel syndrome 2. As a result, we have created new and innovative product Spasmoil, designed to reduce the symptoms of indigestion. The new medicinal product contains 100% natural essential oils – peppermint and fennel essential oils, which help to reduce bloating, as well as have an antispasmodic effect”.
Lotos Pharma has invested EUR 42,000 in the development and implementation of the new product. Currently, SpasmoilTM is already available in Latvian pharmacies, as well as its introduction in export markets is planned, as during participation in the international exhibition VitafoodsTM Europe 2019 in Switzerland, SpasmoilTM was included in the new product area and gained great interest from exhibitors and visitors.
¹ The survey has been conducted on 12 May 2019 by Lotos Pharma. 44 respondents participated in the survey.
² Enck P., Therapy options in irritable bowel syndrome. Eur J Gastroenterol Hepatol. 2010 Dec; 22(12):1402‐11. Review 121 trials in the last 35 years (used Jadad scale for quality assessment).